Aura Biosciences SVP Amy Elazzouzi Sells Shares Valued at $10,881

Aura Biosciences, Inc. (NASDAQ:AURA) recently witnessed a stock sale by its Senior Vice President (SVP), Amy Elazzouzi. On Tuesday, February 18th, Elazzouzi sold 1,404 shares of the company's stock. The shares were sold at an average price of $7.75, totaling $10,881. Following this transaction, Elazzouzi now directly holds 82,278 shares in the company, which are valued at approximately $637,654.50. This sale represents a decrease of 1.68% in her ownership of the stock.

The transaction was made public through a filing with the Securities and Exchange Commission (SEC), which is accessible on their official website.

Aura Biosciences Stock Activity

On the day of the sale, Aura Biosciences' shares were trading down by $0.30, bringing the stock price to $7.65. About 213,354 shares changed hands, compared to the average trading volume of 139,966 shares. Over the past year, the stock has reached a low of $6.63 and a high of $12.38. The company's 50-day simple moving average stands at $8.07, while the 200-day simple moving average is $8.76. The current market capitalization for Aura Biosciences is approximately $382.12 million, with a price-to-earnings (P/E) ratio of -4.42 and a beta of 0.29.

Analytical Insights on Aura Biosciences

Recent reports from various equity analysts have reviewed Aura Biosciences' stock. Lifesci Capital upgraded the rating on Aura Biosciences to a "strong-buy" on January 31st. Additionally, HC Wainwright reiterated a "buy" rating and set a target price of $22.00 for the stock in mid-November last year. Currently, five investment analysts have given the stock a 'buy' rating and two have issued a strong 'buy' rating according to MarketBeat.com, indicating that the company holds a consensus rating of "Buy" with a target price of $23.00.

Institutional Investor Activity

Institutional investors have been actively adjusting their stakes in Aura Biosciences. Long Focus Capital Management LLC reported a 123.9% increase in its position by acquiring an additional 1,404,228 shares, now totaling 2,537,774 shares valued at $20.86 million. Similarly, Levin Capital Strategies L.P. enhanced its stake by 169.1%, owning 1,247,619 shares worth $10.25 million after acquiring 783,984 additional shares. Other notable trades include a new acquisition by B Group Inc. valued at $3.88 million in the fourth quarter, and Franklin Resources Inc. increasing its stake by 14.8% in the third quarter, owning 1,668,960 shares worth $15.57 million. As of now, institutional investors and hedge funds collectively own 96.75% of the company's stock.

Company Overview

Aura Biosciences, Inc. is a clinical-stage biotechnology company that focuses on developing precision immunotherapies aimed at treating various solid tumors. Utilizing its proprietary platform, the company targets solid tumors by using virus-like particles either conjugated with drugs or loaded with nucleic acids to form virus-like drug conjugates.

Aura, Stock, Sale